Quick Hits: Heartburn Drugs and Stroke Risk & FDA Official Stands by Controversial Drug Approval

Quick Hits: Transvaginal Mesh Pulled, New Weight Loss Drug & More

Taking common heartburn medications, such as Prilosec and Nexium, may boost your risk for a stroke. The drugs, known as PPIs (proton pump inhibitors), have been associated with vascular issues such as heart attacks, kidney disease and dementia. Based on the medical records of more than 244,000 Danish patients who had received an endoscopy, those who were taking a PPI had a 21% higher overall stroke risk, researchers said in a presentation at the American Heart Association’s annual meeting this week. The greater the dose of a PPI taken, the higher the stroke risk, they added, noting those who took the lowest doses of the antacids had only a slight or no increased risk. There was no higher risk with H2 blockers, another class of acid-reducing drugs that includes Pepcid and Zantac. Posted November 15, 2016. Via American Heart Association.

A top FDA official is defending the agency’s recent decision to approve a controversial drug even though the principal study included just 12 subjects, no placebo arm and questionable efficacy. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, told the Boston Globe that she is “very comfortable” with the decision to approve Exondys 51, the first drug to treat Duchenne muscular dystrophy. Although the FDA commissioner can make the final decision on a drug’s approval, it is widely understood that Woodcock’s recommendation to approve was accepted by the head of the agency. However, Woodcock admitted that the clinical study conducted by Sarepta, the developer of Exondys 51, “left so many questions.” But she noted, “You can have a pretty bad development program, and if you cross the finish line we might approve it anyway.” Woodcock added that input from patients also figures in the FDA’s decisions, calling them “experts in their diseases.” Posted November 16, 2016. Via Boston Globe.


Jonathan Block

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

FDA Recalls Metformin and NP Thyroid

FDA Recalls Metformin and NP Thyroid

The FDA has issued a recall of two drugs–NP Thyroid and Metformin–after testing revealed that they weren’t up to code. Read more below, and if you’re taking either medication, please be sure to contact your doctor for how to continue treatment responsibly.  NP Thyroid Recalled Thirteen lots of NP Thyroid,…

Can Convalescent Plasma Treat COVID-19 Patients?

Can Convalescent Plasma Treat COVID-19 Patients?

One of the most promising treatments for COVID-19 is convalescent plasma, a component of blood. People who have been infected with the virus and are now healthy have developed COVID-19-fighting antibodies, which, the theory is, can be given to people currently sick with COVID-19 so that those antibodies can boost…

  • Advertisement